| Cas No.: | 2227102-46-5 |
| pH value: | Corresponds to reference standard: PASS |
| Non-reduced CE-SDS: | >95% |
| SEC-HPLC: | >95% |
| Isoelectric Point: | Corresponds to reference standard |
| Osmolality: | Corresponds to reference standard: PASS |
| Peptide mapping: | Corresponds to reference standard: PASS |
| N-terminal sequence: | Corresponds to reference standard: PASS |
| Description: | Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1]. |
| In Vitro: | Patritumab deruxtecan exhibits activity against breast cancer cells expressing HER3 mutations, regardless of HER2 overexpression [1]. Patritumab deruxtecan (0-100 nM) binds to the surface of all HER3 mutant variants and HER3WT MDA-MB-231 cells in a concentration-dependent manner but does not bind to HER3EV cells [1]. |
| References: | [1]. Koyama K, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022 May 3;17(5):e0267027. |
MSDS
